Jazz Pharmaceuticals (JAZZ) PT Lowered to $180 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $214.44 --0%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
Stifel analyst Annabel Samimy lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $180.00 (from $185.00) while maintaining a Buy rating.
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $319 at Morgan Stanley
- Jazz Pharmaceuticals (JAZZ) PT Raised to $305 at RBC Capital
- Rede D`Or Sao Luiz SA (RDOR3:BZ) PT Lowered to BRL44 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
